Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience
Ruizhi Zhao,1 Yuchao Ma,1 Siran Yang,1 Qingfeng Liu,1 Yuan Tang,1 Kai Wang,1 Ye Zhang,1 Nan Bi,1 Hongmei Zhang,2 Junlin Yi,1 Yexiong Li,1 Jingwei Luo,1 Jianping Xiao1 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Acade...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-11-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/hypofractionated-radiotherapy-for-35-patients-with-adrenal-metastases--peer-reviewed-article-CMAR |
| _version_ | 1819009499436941312 |
|---|---|
| author | Zhao R Ma Y Yang S Liu Q Tang Y Wang K Zhang Y Bi N Zhang H Yi J Li Y Luo J Xiao J |
| author_facet | Zhao R Ma Y Yang S Liu Q Tang Y Wang K Zhang Y Bi N Zhang H Yi J Li Y Luo J Xiao J |
| author_sort | Zhao R |
| collection | DOAJ |
| description | Ruizhi Zhao,1 Yuchao Ma,1 Siran Yang,1 Qingfeng Liu,1 Yuan Tang,1 Kai Wang,1 Ye Zhang,1 Nan Bi,1 Hongmei Zhang,2 Junlin Yi,1 Yexiong Li,1 Jingwei Luo,1 Jianping Xiao1 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of ChinaCorrespondence: Jianping Xiao; Jingwei LuoNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences, Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86-10-87788281; Tel +86-10-87788288Fax +86-10-67706153Email jpxiao8@163.com; jingwei-luo@outlook.comObjective: To investigate the clinical outcomes of hypofractionated radiotherapy for adrenal metastases.Materials and Methods: We retrospectively reviewed patients diagnosed with adrenal metastases and treated with hypofractionated radiotherapy, who did not receive adrenalectomy or have disease progression after chemotherapy, from 2007 to 2019. The Kaplan–Meier method was used to estimate local control rate (LCR), progression-free survival (PFS), and overall survival (OS). Univariate analysis was performed using Log rank test.Results: Thirty-five patients with 42 lesions were enrolled, and the lung was the most common primary site (80.0%). The median follow-up time was 46.4 months. The median volume of GTV and PTV was 23.2 cm3 (range: 3.5– 97.8 cm3) and 38.3 cm3 (range: 10.2– 135.6 cm3), respectively. The main dose regimens were 60 Gy delivered in 4– 15 fractions, with the median dose of PTV being 60 Gy (range: 40– 66.3 Gy) and the biologically effective dose (BED) being 84 Gy (range: 56– 110 Gy). The 1-year and 2-year LCR, OS, and PFS were 92.7% and 88.1%, 76.9% and 45.4%, and 25.1% and 14.4%, respectively. Univariate analysis showed that chemotherapy, disease-free interval from primary disease diagnosis to adrenal metastases diagnosis, and age were significant factors for LCR, OS, and PFS, respectively (p=0.017, 0.049, and 0.004, respectively). No more than grade III toxicities were observed.Conclusion: As a non-invasive approach, hypofractionated radiotherapy is safe and effective for metastatic adrenal lesions, without serious complications.Keywords: adrenal metastases, hypofractionated radiotherapy, prognosis, toxicities |
| first_indexed | 2024-12-21T00:57:20Z |
| format | Article |
| id | doaj.art-d2f232ea7c9843f185ab3e92d9bd8d06 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-21T00:57:20Z |
| publishDate | 2020-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-d2f232ea7c9843f185ab3e92d9bd8d062022-12-21T19:21:15ZengDove Medical PressCancer Management and Research1179-13222020-11-01Volume 12115631157159238Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution ExperienceZhao RMa YYang SLiu QTang YWang KZhang YBi NZhang HYi JLi YLuo JXiao JRuizhi Zhao,1 Yuchao Ma,1 Siran Yang,1 Qingfeng Liu,1 Yuan Tang,1 Kai Wang,1 Ye Zhang,1 Nan Bi,1 Hongmei Zhang,2 Junlin Yi,1 Yexiong Li,1 Jingwei Luo,1 Jianping Xiao1 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of ChinaCorrespondence: Jianping Xiao; Jingwei LuoNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences, Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86-10-87788281; Tel +86-10-87788288Fax +86-10-67706153Email jpxiao8@163.com; jingwei-luo@outlook.comObjective: To investigate the clinical outcomes of hypofractionated radiotherapy for adrenal metastases.Materials and Methods: We retrospectively reviewed patients diagnosed with adrenal metastases and treated with hypofractionated radiotherapy, who did not receive adrenalectomy or have disease progression after chemotherapy, from 2007 to 2019. The Kaplan–Meier method was used to estimate local control rate (LCR), progression-free survival (PFS), and overall survival (OS). Univariate analysis was performed using Log rank test.Results: Thirty-five patients with 42 lesions were enrolled, and the lung was the most common primary site (80.0%). The median follow-up time was 46.4 months. The median volume of GTV and PTV was 23.2 cm3 (range: 3.5– 97.8 cm3) and 38.3 cm3 (range: 10.2– 135.6 cm3), respectively. The main dose regimens were 60 Gy delivered in 4– 15 fractions, with the median dose of PTV being 60 Gy (range: 40– 66.3 Gy) and the biologically effective dose (BED) being 84 Gy (range: 56– 110 Gy). The 1-year and 2-year LCR, OS, and PFS were 92.7% and 88.1%, 76.9% and 45.4%, and 25.1% and 14.4%, respectively. Univariate analysis showed that chemotherapy, disease-free interval from primary disease diagnosis to adrenal metastases diagnosis, and age were significant factors for LCR, OS, and PFS, respectively (p=0.017, 0.049, and 0.004, respectively). No more than grade III toxicities were observed.Conclusion: As a non-invasive approach, hypofractionated radiotherapy is safe and effective for metastatic adrenal lesions, without serious complications.Keywords: adrenal metastases, hypofractionated radiotherapy, prognosis, toxicitieshttps://www.dovepress.com/hypofractionated-radiotherapy-for-35-patients-with-adrenal-metastases--peer-reviewed-article-CMARadrenal metastaseshypofractionated radiotherapyprognosistoxicities |
| spellingShingle | Zhao R Ma Y Yang S Liu Q Tang Y Wang K Zhang Y Bi N Zhang H Yi J Li Y Luo J Xiao J Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience Cancer Management and Research adrenal metastases hypofractionated radiotherapy prognosis toxicities |
| title | Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience |
| title_full | Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience |
| title_fullStr | Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience |
| title_full_unstemmed | Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience |
| title_short | Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience |
| title_sort | hypofractionated radiotherapy for 35 patients with adrenal metastases a single institution experience |
| topic | adrenal metastases hypofractionated radiotherapy prognosis toxicities |
| url | https://www.dovepress.com/hypofractionated-radiotherapy-for-35-patients-with-adrenal-metastases--peer-reviewed-article-CMAR |
| work_keys_str_mv | AT zhaor hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT may hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT yangs hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT liuq hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT tangy hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT wangk hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT zhangy hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT bin hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT zhangh hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT yij hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT liy hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT luoj hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience AT xiaoj hypofractionatedradiotherapyfor35patientswithadrenalmetastasesasingleinstitutionexperience |